The FDA has unveiled its top science and research priorities for FY 2026 under the GDUFA program, including nitrosamine risk, complex drug development, bioequivalence innovations, and the use of AI and modeling to modernize generics regulation.
Federal judge rules nurse practitioners with doctorates cannot use “doctor/Dr.” in advertising or health care settings likely to make patients think they’re physicians.
Air Force reviews cancer risk in missile crews; early analyses show no excess mortality, but exposures to PCBs and benzene prompt vigilance and targeted histories.
On September 25, the U.S. Food and Drug Administration (FDA) removed the Risk Evaluation and Mitigation Strategies (REMS) program for vandetanib, according to an announcement from the agency.
The ASCO Post
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
“These findings indicate that standardized efficacy, safety, and risk assessment reporting remains inadequate for FDA-cleared AI/ML devices, underscoring the need for dedicated regulatory pathways and robust postmarket surveillance to ensure patient safety."